Retatrutide Is Bringing a Hard Look at Health Outcomes
Eli Lilly’s phase‑3 TRIUMPH‑1 trial showed retatrutide delivering unprecedented weight loss, with participants on the top dose shedding an average of 28.3% of body weight after 80 weeks and 45.3% achieving at least a 30% reduction. In a two‑year extension for patients with a BMI ≥ 35, the drug drove a 30.3% loss. Beyond the scale, TRIUMPH‑4 demonstrated marked knee‑pain relief in obese patients with osteoarthritis, while the ongoing TRIUMPH‑Outcomes study is probing cardiovascular and renal event reduction. The data are prompting clinicians to view obesity therapy through a health‑outcome lens rather than pure weight metrics.
The Fascinating Properties of Ivermectin
The post spotlights new research on ivermectin’s anti‑cancer potential while revisiting its historic discovery and essential‑medicine status. It recounts the 2020 Monash in‑vitro study that showed a 5,000‑fold reduction of SARS‑CoV‑2, the 2020 Florida cohort linking the drug to lower...
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual...
Immunome presented detailed Phase 3 RINGSIDE data for its gamma secretase inhibitor varegacestat at the 2026 ASCO meeting. The trial met its primary endpoint, showing an 84% reduction in progression‑free survival risk and a 56% objective response rate versus 9% with...
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Summit Therapeutics presented interim Phase II data from the AK112‑206 trial at ASCO 2026, evaluating ivonescimab combined with mFOLFOX6 in treatment‑naïve, microsatellite‑stable metastatic colorectal cancer. In 49 patients, the regimen achieved a 70.8% objective response rate and a disease control...
ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit From Adding Chemotherapy in Metastatic Prostate Cancer
Veracyte’s Decipher Prostate genomic test was shown in the ENZAMET Phase III trial to predict which men with metastatic prostate cancer benefit from adding docetaxel to standard ADT + enzalutamide therapy. Patients with high Decipher scores (>0.85) and high‑volume disease experienced significantly better...
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: A First-in-Class Epigenetic Silencer for Patients with Hepatitis...
Tune Therapeutics reported Phase 1b/2a data for TUNE‑401, an IV‑delivered LNP‑RNA epigenetic silencer, at the EASL 2026 Congress. The study showed dose‑dependent, durable repression of all key HBV biomarkers, including direct loss of cccDNA‑derived pgRNA and HBeAg in a subset of...
Six ASCO Trials Decoded: Data, Gaps, and Implications
ASCO’s opening day was filled with superlatives, yet the real insight lies in a deeper look at six highlighted trials. Those trials deliver promising efficacy signals but expose gaps such as limited safety follow‑up, short‑term endpoints, and weak control arms....
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including...
Corcept Therapeutics reported overall survival data from its Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab‑paclitaxel in platinum‑resistant ovarian cancer at ASCO 2026. The combination cut the risk of death by 35% (HR 0.65, p = 0.0004) and extended median overall survival to 16.0...
Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides...
Mountain Valley MD reported progress on its patented Quicksome™ sublingual delivery platform, completing initial formulation work on several high‑interest peptides such as BPC‑157, GHK‑Cu, KPV, SNAP‑8 and retatrutide. The six‑month effort expanded the company’s lab capabilities and demonstrated stability and...
Seven-Year Analysis From Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
Pfizer reported seven‑year follow‑up from the Phase 3 CROWN trial, showing that lorlatinib (LORBRENA) achieved a 55% progression‑free survival (PFS) rate versus just 3% for crizotinib (XALKORI). Median PFS was not reached for LORBRENA, translating to an 81% reduction in risk...
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
The World Health Organization has named three experimental therapies—Mapp Biopharmaceutical’s MBP134, Regeneron’s maftivimab, and Gilead’s remdesivir—as priority candidates for treating the Bundibugyo strain of Ebola. The agency urges immediate clinical trials as the outbreak spreads across the Democratic Republic of...
Regulatory and Scientific Frontiers in Drug Repurposing: Accelerating Therapeutic Innovations for Unmet Medical Needs + Examples of Repurposed Drugs
On May 11, 2026 the FDA unveiled a formal drug‑repurposing program aimed at accelerating clinical trials for approved compounds targeting chronic, rare and underserved conditions. The initiative builds on prior legislation such as the Best Pharmaceuticals for Children Act and...
Beren Therapeutics Announces FDA Extension of Review Period for New Drug Application (NDA) for Adrabetadex for the Treatment of Infantile-Onset...
Beren Therapeutics announced that the FDA has extended the review period for its New Drug Application for adrabetadex, a cyclodextrin‑based therapy for infantile‑onset Niemann‑Pick disease type C, by three months. The new PDUFA target action date is November 17, 2026, following a major...
FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant
The FDA’s Vaccines and Related Biological Products Advisory Committee voted to update COVID‑19 vaccine compositions for the 2026‑2027 season to target the XFG variant, which now accounts for more than half of U.S. cases. The recommendation follows a WHO call...
One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and...
Verve Therapeutics reported Phase 1b Heart‑2 data for its gene‑editing LDL therapy VERVE‑102 in the New England Journal of Medicine. A single intravenous infusion achieved up to 88% PCSK9 knock‑down and a 62% reduction in LDL‑C that persisted for 18...